JAMA Oncology published McDonald et al
research regarding the efficacy of digital breast tomosynthesis (DBT) on recall
rates versus that of digital mammography (DM), and also its
sustainability over the long term.
The study was a retrospective analysis of a
total of 44468 screening events performed on 23958 women whose average age was 56
years and were followed over a period of 4 years.
Recall
rates rose slightly for years 1 to 3 of DBT (88, 90, and 92 per 1000 screened,
respectively) but remained significantly reduced compared with the DM zero rate
of 104 per 1000 screened. The cancer cases per recalled patients continued to
rise from DM zero rate of 4.4% to 6.2% for years 1 to 3 of DBT, respectively.
Outcomes assessed for the most recent screening for individual women undergoing
only 1, 2, or 3 DBT screenings during the study period demonstrated decreasing
recall rates of 130, 78, and 59 per 1000 screened, respectively (P < .001).
Interval cancer rates, determined using available follow-up data, decreased
from 0.7 per 100 women screened with the use of DM to 0.5 per 1000 screened
with the use of DBT.
Digital
breast tomosynthesis screening outcomes are sustainable, with significant
recall reduction, increasing cancer cases per recalled patients, and a decline
in interval cancers.